Syncom Formulation (India) (NSE:SYNCOMF) Risk Assessment

View and export this data going back to 2022. Start your Free Trial

What is Syncom Formulation (India) Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Syncom Formulation (India) is: Moderate Risk: Sensitive, better choose undervalued stock.

Competitive Comparison of Syncom Formulation (India)'s Risk Assessment

For the Drug Manufacturers - Specialty & Generic subindustry, Syncom Formulation (India)'s Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Syncom Formulation (India)'s Risk Assessment Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Syncom Formulation (India)'s Risk Assessment distribution charts can be found below:

* The bar in red indicates where Syncom Formulation (India)'s Risk Assessment falls into.

Syncom Formulation (India) (NSE:SYNCOMF) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Syncom Formulation (India) Risk Assessment Related Terms

Thank you for viewing the detailed overview of Syncom Formulation (India)'s Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Syncom Formulation (India) (NSE:SYNCOMF) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Syncom Formulation (India) Ltd (NSE:SYNCOMF) » Definitions » Risk Assessment

Traded in Other Exchanges

524470:India

Address

207, Saket Nagar, Near Saket Club, Indore, MP, IND, 452018

Website

https://www.sfil.in

Syncom Formulation (India) Ltd is in the business of pharmaceuticals. The company operates through three segments including manufacturing and dealings in Pharmaceutical drugs and formulations, Trading of commodities, and Renting of property. It manufactures and markets pharmaceutical formulation products in various dosage forms like tablets, capsules, liquids orals, liquids vials, ampoule injections and dry vial injections, dry syrups, ointments, inhalers, and Herbals. The company's product includes generic, antiviral, antidepressant, cough suppressant, electrolyte, histamine, estrogen, and much more. It generates maximum revenue through the Pharmaceutical drugs and formulations segment.

Syncom Formulation (India) (NSE:SYNCOMF) Headlines

No Headlines